Table 3 The 46 most common ART regimens purchased in 2016, by regimen categorya
Regimen categoryb | N = 1786 n (%) |
|---|---|
Category 1: Guideline recommended regimens | 998 (55.9) |
 dolutegvravir/abacavir/lamivudine | 419 (42.0) |
 elvitegravir/cobicistat/TAF/emtricitabine | 256 (25.7) |
 dolutegravir + [TDF/emtricitabine or TAF/emtricitabine] | 146 (14.6) |
 raltegravir + [TDF/emtricitabine or TAF/emtricitabine] | 89 (8.9) |
 elvitegravir/cobicistat/TDF/emtricitabine | 61 (6.1) |
 r/darunavir + [TDF/emtricitabine or TAF/emtricitabine] | 27 (2.7) |
Category 2: Guideline alternative regimens | 448 (25.1) |
 efavirenz/TDF/emtricitabine | 207 (46.2) |
 rilpivirine/TDF/emtricitabine | 190 (42.4) |
 [r/atazanavir or c/atazanavir] + [TDF/emtricitabine or TAF/emtricitabine] | 44 (9.8) |
 [c/darunavir or r/darunavir] + abacavir/lamivudine | 7 (1.6) |
 c/darunavir + [TDF/emtricitabine or TAF/emtricitabine] | 0 |
 efavirenz + TAF/emtricitabine | 0 |
 rilpivirine/TAF/emtricitabine | 0 |
Category 3: Guideline other regimens | 48 (2.7) |
 raltegravir + abacavir/lamivudine | 15 (31.3) |
 efavirenz + abacavir/lamivudine | 14 (29.2) |
 r/darunavir + raltegravirc | 11 (22.9) |
 [r/atazanavir or c/atazanavir] + abacavir/lamivudine | 8 (16.7) |
 lopinavir/ritonavir + lamivudinec | 0 |
Category 4: Other combinations of guideline-recommended ART | 89 (5.0) |
 r/darunavir + dolutegravir | 15 (16.9) |
 r/darunavir + raltegravir + TDF/emtricitabine | 13 (14.6) |
 elvitegravir/cobicistat/TAF/emtricitabine + darunavir | 10 (11.2) |
 r/lopinavir + TDF/emtricitabine | 9 (10.1) |
 dolutegravir/abacavir/lamivudine + TDF | 7 (7.8) |
 TDF/emtricitabine alone | 6 (6.7) |
 elvitegravir/cobicistat/TAF/emtricitabine + atazanavir | 4 (4.5) |
 r/darunavir + lamivudine | 4 (4.5) |
 r/atazanavir + abacavir/lamivudine + TDF | 3 (3.4) |
 dolutegravir/abacavir/lamivudine + r/darunavir | 3 (3.4) |
 r/darunavir + dolutegravir + lamivudine | 3 (3.4) |
 dolutegravir + rilpivirine + lamivudine | 3 (3.4) |
 dolutegravir + rilpivirine | 3 (3.4) |
 r/darunavir alone | 3 (3.4) |
 r/darunavir + dolutegravir + TDF/emtricitabine | 3 (3.4) |
Category 5: Medications not recommended for first-line ART regimens but used in special circumstances | 203 (11.4)d |
 nevirapine-containing regimend | 157 |
 etravirine-containing regimen | 20 |
 unboosted atazanavir or darunavir-containing regimen | 18 |
 zidovudine/lamivudine-containing regimenc | 16 |
 maraviroc-containing regimen | 4 |
 tipranavir-containing regimen | 0 |
 enfurvitide-containing regimen | 0 |